Short interest in IGM Biosciences Inc (NASDAQ:IGMS) decreased during the last reporting period, falling from 4.02M to 3.68M. This put 24.46% of the company's publicly available shares short.

Analyst Michael Ulz of Morgan Stanley maintained a Hold rating on IGM Biosciences (IGMS – Research Report), retaining the price target of $12.00. Michael Ulz’s rating is based on the current ...

Igm Biosciences (IGMS) has disclosed a new risk, in the Share Price & Shareholder Rights category. Igm Biosciences faces significant risks that could adversely impact its business and financial ...

IGM Biosciences (NASDAQ:IGMS – Free Report) had its price objective increased by Royal Bank of Canada from $17.00 to $20.00 in a research note published on Friday morning, Benzinga reports.

For example, IGM Biosciences (NASDAQ:IGMS) shareholders have done very well over the last year, with the share price soaring by 181%. Having said that, unprofitable companies are risky because ...